Uy Ear
Stock Analyst at Mizuho Securities
(4.26)
# 1,497
Out of 4,649 analysts
601
Total ratings
45.8%
Success rate
9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Reiterated: Buy | $19 | $4.80 | +295.83% | 38 | Aug 11, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $8.84 | +352.49% | 29 | Aug 11, 2026 | |
| INAB IN8bio | Maintained: Buy | $4 | $1.10 | +263.64% | 17 | Aug 11, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $65 | $49.06 | +32.49% | 61 | Aug 7, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $91 | $68.57 | +32.71% | 13 | Aug 7, 2026 | |
| ARQT Arcutis Biotherapeutics | Reiterated: Buy | $35 → $36 | $26.19 | +37.46% | 164 | Aug 6, 2026 | |
| EOLS Evolus | Reiterated: Buy | $15 | $8.16 | +83.94% | 51 | Aug 5, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $35 → $36 | $28.24 | +27.48% | 40 | Aug 4, 2026 | |
| QURE uniQure | Reiterated: Buy | $68 | $48.62 | +39.86% | 27 | Jul 29, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $31 | $18.10 | +71.27% | 64 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $285 | $84.69 | +236.52% | 1 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $85 | $34.91 | +143.48% | 34 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $146 → $175 | $152.72 | +14.59% | 38 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.35 | n/a | 13 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.75 | n/a | 9 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $4.31 | n/a | 1 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $36.77 | n/a | 1 | Jul 10, 2019 |
Relmada Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $19
Current: $4.80
Upside: +295.83%
Cartesian Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $40
Current: $8.84
Upside: +352.49%
IN8bio
Aug 11, 2026
Maintained: Buy
Price Target: $4
Current: $1.10
Upside: +263.64%
Alkermes
Aug 7, 2026
Reiterated: Buy
Price Target: $65
Current: $49.06
Upside: +32.49%
MBX Biosciences
Aug 7, 2026
Reiterated: Buy
Price Target: $91
Current: $68.57
Upside: +32.71%
Arcutis Biotherapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $35 → $36
Current: $26.19
Upside: +37.46%
Evolus
Aug 5, 2026
Reiterated: Buy
Price Target: $15
Current: $8.16
Upside: +83.94%
ACADIA Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $35 → $36
Current: $28.24
Upside: +27.48%
uniQure
Jul 29, 2026
Reiterated: Buy
Price Target: $68
Current: $48.62
Upside: +39.86%
Sarepta Therapeutics
Jul 10, 2026
Maintained: Buy
Price Target: $31
Current: $18.10
Upside: +71.27%
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $285
Current: $84.69
Upside: +236.52%
Jun 10, 2026
Reiterated: Buy
Price Target: $85
Current: $34.91
Upside: +143.48%
Dec 12, 2025
Maintained: Hold
Price Target: $146 → $175
Current: $152.72
Upside: +14.59%
Aug 18, 2023
Rated: Hold
Price Target: n/a
Current: $1.35
Upside: n/a
Aug 11, 2023
Rated: Hold
Price Target: n/a
Current: $2.75
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $4.31
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $36.77
Upside: n/a